West Pharmaceutical Services Exceeds Earnings Expectations and Raises Full-Year Guidance
West Pharmaceutical Services (WST) reported strong third-quarter results, with adjusted EPS of $2.66 on sales of $874.5 million, significantly beating analyst estimates of $2.20 per share. The company raised its full-year adjusted EPS guidance to a range of $9.38 to $9.48, up from previous projections. While the surge in GLP-1 demand from companies like Eli Lilly (LLY) provides a significant tailwind for injectable drug-delivery components, West's growth is increasingly driven by its high-value proprietary products. Proprietary product sales grew 12.6%, with high-value components specifically rising 20.3% and now accounting for 53% of total sales. This shift toward premium products has improved operating leverage, allowing earnings to grow at a faster rate than organic sales. Management expects operating margins to expand by nearly 300 basis points this year, supported by disciplined capital spending and regulatory-driven demand.
Topics: earnings report GLP-1 demand guidance increase pharmaceutical manufacturing revenue growth
Part of the story Fiverr Raises Full-Year Revenue Guidance Amid Strategic Shift Toward AI and High-Value Projects (13 articles)